Ruxolitinib plus decitabine in post-MPN AML
The outcomes of patients with post-myeloproliferative neoplasm acute myeloid leukemia (post-MPN AML) are poor, with no standard therapy. In this interview, Farhad Ravandi, MD, from the University of T...
Author: VJHemOnc
Added: 02/09/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Leukemia | Myeloproliferative Disorders